144,810 Shares in Vera Therapeutics, Inc. $VERA Acquired by Nicholas Investment Partners LP

Nicholas Investment Partners LP acquired a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 144,810 shares of the company’s stock, valued at approximately $7,333,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after acquiring an additional 236 shares during the period. Los Angeles Capital Management LLC bought a new stake in Vera Therapeutics in the fourth quarter worth approximately $46,000. Quantbot Technologies LP bought a new stake in Vera Therapeutics in the second quarter worth approximately $51,000. Tower Research Capital LLC TRC increased its holdings in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after purchasing an additional 639 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Trading Up 1.8%

Shares of Vera Therapeutics stock opened at $34.26 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05. The stock has a 50 day moving average price of $37.02 and a two-hundred day moving average price of $41.38. The stock has a market capitalization of $2.46 billion, a PE ratio of -6.18 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the firm earned ($0.81) earnings per share. As a group, equities analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

VERA has been the subject of a number of research analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. HC Wainwright lifted their target price on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Wednesday, March 11th. Finally, William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vera Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $10,362,498.20. The trade was a 8.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by corporate insiders.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.